724 related articles for article (PubMed ID: 33325008)
61. Incretin hormones: Their role in health and disease.
Nauck MA; Meier JJ
Diabetes Obes Metab; 2018 Feb; 20 Suppl 1():5-21. PubMed ID: 29364588
[TBL] [Abstract][Full Text] [Related]
62. Patient-Reported Outcomes in People with Type 2 Diabetes Receiving Tirzepatide in the SURPASS Clinical Trial Programme.
Boye KS; Thieu VT; Sapin H; Lee CJ; Landó LF; Brown K; Bray R; Wiese RJ; Patel H; Rodríguez Á; Yu M
Diabetes Ther; 2023 Nov; 14(11):1833-1852. PubMed ID: 37526908
[TBL] [Abstract][Full Text] [Related]
63. Tirzepatide, a New Era of Dual-Targeted Treatment for Diabetes and Obesity: A Mini-Review.
Chavda VP; Ajabiya J; Teli D; Bojarska J; Apostolopoulos V
Molecules; 2022 Jul; 27(13):. PubMed ID: 35807558
[TBL] [Abstract][Full Text] [Related]
64. The impact of tirzepatide and glucagon-like peptide 1 receptor agonists on oral hormonal contraception.
Skelley JW; Swearengin K; York AL; Glover LH
J Am Pharm Assoc (2003); 2024; 64(1):204-211.e4. PubMed ID: 37940101
[TBL] [Abstract][Full Text] [Related]
65. A Case Report of Systemic Allergic Reaction to the Dual Glucose-Dependent Insulinotropic Polypeptide/Glucagon-Like Peptide-1 Receptor Agonist Tirzepatide.
Le TTB; Minh LHN; Devi P; Islam N; Sachmechi I
Cureus; 2024 Jan; 16(1):e51460. PubMed ID: 38298324
[TBL] [Abstract][Full Text] [Related]
66. Effects of Novel Dual GIP and GLP-1 Receptor Agonist Tirzepatide on Biomarkers of Nonalcoholic Steatohepatitis in Patients With Type 2 Diabetes.
Hartman ML; Sanyal AJ; Loomba R; Wilson JM; Nikooienejad A; Bray R; Karanikas CA; Duffin KL; Robins DA; Haupt A
Diabetes Care; 2020 Jun; 43(6):1352-1355. PubMed ID: 32291277
[TBL] [Abstract][Full Text] [Related]
67. Tirzepatide and prevention of chronic kidney disease.
Bosch C; Carriazo S; Soler MJ; Ortiz A; Fernandez-Fernandez B
Clin Kidney J; 2023 May; 16(5):797-808. PubMed ID: 37151412
[TBL] [Abstract][Full Text] [Related]
68. Tirzepatide for the treatment of adults with type 2 diabetes: An endocrine perspective.
De Block C; Bailey C; Wysham C; Hemmingway A; Allen SE; Peleshok J
Diabetes Obes Metab; 2023 Jan; 25(1):3-17. PubMed ID: 35929488
[TBL] [Abstract][Full Text] [Related]
69. Obesity pharmacotherapy: incretin action in the central nervous system.
Boer GA; Hay DL; Tups A
Trends Pharmacol Sci; 2023 Jan; 44(1):50-63. PubMed ID: 36462999
[TBL] [Abstract][Full Text] [Related]
70. Evaluating the Efficacy and Safety of Tirzepatide on Glycaemic and Non-glycaemic Outcomes in Diabetes: A Systematic Review of Meta-Analyses.
Kaore S; B B; Khasbage S; Atal S
Cureus; 2024 Mar; 16(3):e56939. PubMed ID: 38665722
[TBL] [Abstract][Full Text] [Related]
71. New Developments in Pharmacological Treatment of Obesity and Type 2 Diabetes-Beyond and within GLP-1 Receptor Agonists.
Sztanek F; Tóth LI; Pető A; Hernyák M; Diószegi Á; Harangi M
Biomedicines; 2024 Jun; 12(6):. PubMed ID: 38927527
[TBL] [Abstract][Full Text] [Related]
72. Diabetes and obesity treatment based on dual incretin receptor activation: 'twincretins'.
Skow MA; Bergmann NC; Knop FK
Diabetes Obes Metab; 2016 Sep; 18(9):847-54. PubMed ID: 27160961
[TBL] [Abstract][Full Text] [Related]
73. Tirzepatide: A novel cardiovascular protective agent in type 2 diabetes mellitus and obesity.
Sardar MB; Nadeem ZA; Babar M
Curr Probl Cardiol; 2024 May; 49(5):102489. PubMed ID: 38417475
[TBL] [Abstract][Full Text] [Related]
74. Efficacy and Safety of Tirzepatide in Patients with Type 2 Diabetes Mellitus: A Systematic Review and Meta-Analysis of Randomized Phase II/III Trials.
Bhagavathula AS; Vidyasagar K; Tesfaye W
Pharmaceuticals (Basel); 2021 Sep; 14(10):. PubMed ID: 34681215
[TBL] [Abstract][Full Text] [Related]
75. Effect of dual glucose-dependent insulinotropic peptide/glucagon-like peptide-1 receptor agonist on weight loss in subjects with obesity.
Zaffina I; Pelle MC; Armentaro G; Giofrè F; Cassano V; Sciacqua A; Arturi F
Front Endocrinol (Lausanne); 2023; 14():1095753. PubMed ID: 36909312
[TBL] [Abstract][Full Text] [Related]
76. Research Progress on the GIP/GLP-1 Receptor Coagonist Tirzepatide, a Rising Star in Type 2 Diabetes.
Ma Z; Jin K; Yue M; Chen X; Chen J
J Diabetes Res; 2023; 2023():5891532. PubMed ID: 37096236
[TBL] [Abstract][Full Text] [Related]
77. GIPR agonism mediates weight-independent insulin sensitization by tirzepatide in obese mice.
Samms RJ; Christe ME; Collins KA; Pirro V; Droz BA; Holland AK; Friedrich JL; Wojnicki S; Konkol DL; Cosgrove R; Furber EPC; Ruan X; O'Farrell LS; Long AM; Dogra M; Willency JA; Lin Y; Ding L; Cheng CC; Cabrera O; Briere DA; Alsina-Fernandez J; Gimeno RE; Moyers JS; Coskun T; Coghlan MP; Sloop KW; Roell WC
J Clin Invest; 2021 Jun; 131(12):. PubMed ID: 34003802
[TBL] [Abstract][Full Text] [Related]
78. The insulinotropic actions of glucose-dependent insulinotropic polypeptide (GIP) and glucagon-like peptide-1 (7-37) in normal and diabetic subjects.
Elahi D; McAloon-Dyke M; Fukagawa NK; Meneilly GS; Sclater AL; Minaker KL; Habener JF; Andersen DK
Regul Pept; 1994 Apr; 51(1):63-74. PubMed ID: 8036284
[TBL] [Abstract][Full Text] [Related]
79. GIPR/GLP-1R dual agonist therapies for diabetes and weight loss-chemistry, physiology, and clinical applications.
Campbell JE; Müller TD; Finan B; DiMarchi RD; Tschöp MH; D'Alessio DA
Cell Metab; 2023 Sep; 35(9):1519-1529. PubMed ID: 37591245
[TBL] [Abstract][Full Text] [Related]
80. Effect of the Dual Glucose‐Dependent Insulinotropic Peptide/Gulcagon‐like Peptide 1 Receptor Agonist Tirzepatide on Lipid Profile and Waist Circumference: A Systematic Review and Meta‐analysis.
Yu D; Shen S; Zhang J; Wang Q
Clin Ther; 2023 Aug; 45(8):787-796. PubMed ID: 37455226
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
